An mRNA Vaccine against SARS-CoV-2 – Preliminary Report

ByThe Short Paper

Article

This was a phase 1 trial where they tested an mRNA vaccine on 45 patients ages 18 to 55 years old. There were 3 different dose groups, n=15. Each dose group received a total of 2 vaccinations 28 days apart. They found dose appropriate anti-SARS-CoV-2 titer increases. There were some minor side effects “fatigue, chills, headache, myalgia, and pain at the injection site.” These side effects occurred in more than half the participants.

TL;DR Phase 1 trial of 45 patients for an mRNA vaccine induced an anti-SARS-CoV-2 immune response in all participants

Similar Posts

Choosing Your Search Engine on Android: How Auctions Matter

ByThe Short Paper

Choice Screen Auctions In Europe, you can now choose your search engine on Android instead of using Google’s automatically. However, a small change in how these choices are made, either based on how often they appear or how often they are installed, can affect which search engines win and how much of the market they…

Potently neutralizing and protective human antibodies against SARS-CoV-2

ByThe Short Paper

Article The study looked at COVID-19 antigens, specifically the ones related to a “spike” antigen that interacts with ACE2 and helps to infect people. The antibodies specifically were made to prevent interaction of the spike and ACE2. The antibodies were  COV2-2196 and COV2-2130. They were found to act in a synergistic manner with one another. In…

Unlocking the Power of Chemical Timekeepers: Oscillatory Systems and Catalytic Wonders

ByThe Short Paper

A catalytically active oscillator made from small organic molecules Oscillatory systems are like regulators in our body, controlling many important processes like metabolism, cell division, and even things like our daily rhythm and heartbeat. Scientists were inspired by chemical oscillations found in non-living things and created synthetic oscillators that work like timekeepers. These synthetic oscillators…

A Key to Protecting Brain Cells in Alzheimer’s, MEG3

ByThe Short Paper

MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease In Alzheimer’s disease, the loss of brain cells is a major problem, but we don’t fully understand why it happens. Scientists did an experiment where they put human and mouse brain cells into mice with Alzheimer’s. They found that only the human brain cells showed…

Simple Summary – Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

ByThe Short Paper

Link to the paper: https://www.ncbi.nlm.nih.gov/pubmed/31367040 Systemic inflammation from cancer is linked to a poor outcome for cancer patients. Inflammation is a biochemical response in the body where white blood cells and other cells secrete substances to protect the body from infections, diseases, and injuries. However, this does not always necessarily turn out well for the…

Second-Best Fairness: The Trade-off between False Positives and False Negatives

ByThe Short Paper

In economics, a key question is how to create effective policies when things aren’t perfect. This often means balancing between helping some who may not entirely deserve it (false positives) and not helping others who may deserve it (false negatives). This study, conducted in the United States and Norway through large-scale experiments, reveals that most…